Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders

Paulis, Ludovit; Foulquier, Sébastien; Namsolleck, Pawel; Recarti, Chiara; Steckelings, Muscha; Unger, Thomas

Published in:
Drugs

DOI:
10.1007/s40265-015-0509-4

Publication date:
2016

Document version
Publisher's PDF, also known as Version of record

Document license
CC BY-NC

Citation for published version (APA):
Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders

Ludovit Paulis¹,² · Sébastien Foulquier³ · Pawel Namsolleck³ · Chiara Recarti³ · Ulrike Muscha Stekelings⁴ · Thomas Unger³

Published online: 2 December 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract Cardiovascular and metabolic disorders, such as hypertension, insulin resistance, dyslipidemia or obesity are linked with chronic low-grade inflammation and dysregulation of the renin–angiotensin system (RAS). Consequently, RAS inhibition by ACE inhibitors or angiotensin AT1 receptor (AT1R) blockers is the evidence-based standard for cardiovascular risk reduction in high-risk patients, including diabetics with albuminuria. In addition, RAS inhibition reduces the new onset of diabetes mellitus. Yet, the high and increasing prevalence of metabolic disorders, and the high residual risk even in properly treated patients, calls for additional means of pharmacological intervention. In the past decade, the stimulation of the angiotensin AT2 receptor (AT2R) has been shown to reduce inflammation, improve cardiac and vascular remodeling, enhance insulin sensitivity and increase adiponectin production. Therefore, a concept of dual AT1R/AT2R modulation emerges as a putative means for risk reduction in cardio-metabolic diseases. The approach employing simultaneous RAS blockade (AT1R) and RAS stimulation (AT2R) is distinct from previous attempts of double intervention in the RAS by dual blockade. Dual blockade abolishes the AT1R-linked RAS almost completely with subsequent risk of hypotension and hypotension-related events, i.e. syncope or renal dysfunction. Such complications might be especially prominent in patients with renal impairment or patients with isolated systolic hypertension and normal-to-low diastolic blood pressure values. In contrast to dual RAS blockade, the add-on of AT2R stimulation does not exert significant blood pressure effects, but it may complement and enhance the anti-inflammatory and anti-fibrotic/de-stiffening effects of the AT1R blockade and improve the metabolic profile. Further studies will have to investigate these putative effects in particular for settings in which blood pressure reduction is not primarily desired.

Key Points

The combination of simultaneous RAS blockade (AT1R) and RAS stimulation (AT2R) represents a novel promising therapeutic concept, which is distinct from previous attempts of double intervention in the RAS by dual blockade.

The add-on of AT2R stimulation complements and augments the anti-inflammatory and anti-fibrotic effects of the AT1R blockade.

This combined intervention may address the need for further risk reduction in patients with well-controlled blood pressure or where further blood pressure reduction is not desired, such as in patients with isolated systolic hypertension, with renal dysfunction or in the elderly.
1 Introduction

Cardiovascular mortality remains high world-wide. In Europe, cardiovascular events remain a major cause of premature deaths, being responsible for 42% of all deaths in women and for 38% of all deaths in men aged <75 years [1].

Cardiovascular morbidity and mortality are strongly determined by the presence of metabolic alterations such as different pro-thrombotic states, dyslipidemia, obesity and insulin resistance (with or without its overt clinical manifestation), which are clinically grouped in the metabolic syndrome. The cardio-metabolic syndrome, depending on the definition, usually features at least three of the following dysregulations: obesity (or central obesity), dyslipidemia [hypertriglyceridemia or low high-density lipoprotein (HDL) levels], hypertension or impaired glucose metabolism (impaired fasting glucose, insulin resistance, hyperinsulinemia or diabetes mellitus), while the World Health Organization adds microalbuminuria as a criterion as well [2]. Despite the advances in treatment and prevention of cardiovascular diseases, the continuous rise of metabolic disorders and abnormalities might render the fight for cardiovascular mortality reduction ineffective. The prevalence of overweight and obesity is rising in both developing and developed countries, with 300 million people being obese and 1 billion being overweight world-wide [3]. In the overweight and obese population there is around 40% prevalence of some type of altered glucose metabolism [4].

Cardiac and metabolic dysregulations represent two sides of the cardio-metabolic coin and are interlinked in both directions. In hypertension, vasoconstriction or vascular rarefication was hypothesized to reduce glucose uptake and thus contribute to hyperglycemia per se [5]. The consequences are hyperinsulinemia followed by insulin resistance. On the other hand, there are several mechanisms by which impaired insulin sensitivity contributes to the development of cardiovascular pathologies. Insulin resistance blunts the vasodilator effects of insulin, and chronic hyperinsulinemia increases sympathetic nervous activity, reduces natriuresis, promotes vascular smooth muscle growth, endothelial dysfunction and hypertriglyceridemia with subsequent atherosclerosis, hypertension and vascular events such as myocardial infarction, stroke or peripheral arterial occlusion disease [6].

2 Behind the Scenes: Pathophysiological Considerations

2.1 Inflammation in Cardio-Metabolic Diseases

Below the surface of the overt cardio-metabolic presentations, there is a complex dysregulation of extracellular and intracellular signaling pathways with chronic low-grade inflammation at its core. This “tonic” inflammation is, besides insulin resistance, now recognized as a main etiological factor of obesity-related metabolic disorders [7, 8]. The adipose tissue is on one hand, the target of the inflammatory process; on the other hand, it can also act as its important modulator. Clinically, the blood levels of pro-inflammatory cytokines such as C-reactive protein or interleukin-6 (IL-6) are not only correlated with excess adipose mass [9, 10], but they also decrease along with weight loss [11]. The levels of pro-inflammatory and anti-inflammatory cytokines depend on the number of adipocytes and even more on the secretory profile of the adipose tissue. In the adipose tissue of healthy, lean subjects, CD4+ T_reg cells prevail, producing type 2 T-helper cell (T_h2) anti-inflammatory cytokines such as the IL-4 and IL-13 and thereby stimulating the differentiation of the residing macrophages towards the alternatively activated M2 (F4/80+CD11b+) CD11c− phenotype [12]. This phenotype is characterized by IL-10 production that stimulates the adipocytes to adiponectin production and enhances insulin sensitivity. Adiponectin inhibits the nuclear factor (NF)-κB pathway as well as tumor necrosis factor (TNF)-α signaling and promotes the expression of the peroxisome proliferator-activated receptor (PPAR)-γ co-activator in macrophages, further promoting their M2 phenotype [13]. Adiponectin via 5’ adenosine monophosphate-activated protein kinase (AMPK) and subsequent desensitization of the toll-like receptor (TLR) signaling exhibits anti-inflammatory effects and through the endothelial NOSynthase pathway also cardio-protective effects [14].

High concentrations of saturated free fatty acids via TLR-4, advanced-glycation end-products, or T_h1 type signals [such as interferon-gamma (INF-γ)] secreted by CD8+ T cells down-regulate PPAR-γ in the macrophages and stimulate their differentiation towards the classically activated M1 (F4/80+CD11b+) CD11c+ phenotype [15, 16]. These macrophages produce pro-inflammatory molecules such as TNF-α, IL-6 and the major chemoattractant protein (MCP)-1. Especially MCP-1 via the chemokine receptor type 2 (CCR2) attracts further classically activated macrophages into the adipose tissue thereby increasing their absolute number [17]. Under these conditions, the pro-inflammatory molecules are also generated by the adipocytes, which also produce leptin. Although leptin improves insulin sensitivity and attenuates hyperlipidemia, it shifts macrophage differentiation towards the M1 phenotype, promotes TNF-α and IL-6 production [18, 19] and is thus considered a pro-inflammatory adipokine [14]. Moreover, due to the development of leptin resistance, the beneficial effects of leptin are blunted, despite the high leptin levels in subjects with increased adipose mass [20].

△ Adis
In cells, the pro-inflammatory cytokines release the repression of the nuclear receptor corepressor and subsequently also NF-κB, c-Jun N-terminal kinase (JNK) and phosphoinositide 3-kinase (PI3K) pathways. In macrophages and adipocytes, these pathways lead to the trans-activation of overlapping sets of pro-inflammatory molecules [21, 22] and promote cellular insulin resistance as well as leptin secretion in adipocytes. In both macrophages and adipocytes, the loss of nuclear receptor corepressor activity can be prevented by PPAR-γ activation (e.g. by thiazolidinediones) resulting in reduced inflammation and improved insulin sensitivity. As insulin resistance evolves, the adipose tissue undergoes adipocyte hypertrophy and infiltration by inflammatory cells [7].

### 2.2 Renin–Angiotensin-System Activation in Cardio-Metabolic Diseases

The components of the local renin–angiotensin system (RAS), such as angiotensin I (Ang I), angiotensin-converting enzyme (ACE), angiotensin II (Ang II), angiotensin AT1 receptor (AT1R), angiotensin AT2 receptor (AT2R) as well as alternative enzymes such as cathepsin and chymase, are abundantly expressed in adipocytes and adipose tissue of various organs [23, 24]. Overfeeding in rodents results in increased angiotensinogen formation and increased local Ang II levels, alterations which were observed in human hypertensive obese patients as well [25].

Increased circulatory or local RAS activity is clearly associated with a variety of pathophysiologic processes, including blood pressure elevation, vasoconstriction, vascular and cardiac remodeling, and renal fibrosis [26]. Moreover, there is a distinct pathophysiological connection linking increased RAS activity and the metabolic alterations.

In addition to the hemodynamic link between the vasoconstrictive effects of Ang II and insulin resistance, Ang II opposes the effects of insulin on glucose metabolism in the liver and inhibits glycogen synthetase thereby contributing to insulin resistance [6]. Stimulation of AT1R by Ang II engenders vasoconstriction and hypokalemia, both impairing insulin sensitivity [5, 27]. AT1R activation also inhibits the glucose transporter type 4 (GLUT4) in skeletal muscle and thus reduces insulin sensitivity [28]. Similar effects might be attributed to ACE activity due to increased degradation of bradykinin [29]. Ang II further increases lipogenesis and triacylglyceride content in the adipocytes by increasing fatty acid synthase and glycerol-3-phosphate dehydrogenase [30–32]. Stimulation of the AT1R can also block adipogenesis and adipocyte differentiation thereby reducing insulin sensitivity [33].

Even of higher importance might be the modulatory effects of RAS on inflammatory activity. As described above, chronic inflammation plays a key role in the pathophysiology of the metabolic syndrome. The pro-inflammatory activity of Ang II via its AT1R is well recognized [34]. Among others, AT1R activation stimulates NF-κB, IL-6 and MCP-1 upregulation [35]. In obese mice on high-fat diet, AT1R blockade or AT1R-knock out (AT1R-KO) reduced renal macrophage infiltration, induced a shift from the deleterious M1 to the M2 macrophage phenotype, and prevented renal injury. Finally, AT1R-KO mice displayed lower body fat and cholesterol levels compared to their wild-type controls [36].

### 3 RAS Modulation in Cardio-Metabolic Disease

#### 3.1 Angiotensin AT1 Receptor Blockers

From a clinical point of view, there is a large body of evidence for the reduction of cardiovascular morbidity and mortality by RAS inhibition, in particular in heart failure, hypertensive, diabetic, or generally, in high-risk patients. Large clinical trials have been performed with ACE inhibitors, for example, SOLVD [37], CAPP [38] STOP-2 [39] or HOPE [40] and AT1R blockers (ARBs), for example, CHARM [41], LIFE [42], VALUE [43] or ONTARGET [44].

The cardio-protective effects of RAS blockade observed in these and other trials are consistent with the effects of RAS blockade in subgroups of diabetic patients. In the HOPE trial, the ACE inhibitor ramipril achieved numerically an even higher relative reduction of the primary endpoint (cardiovascular death, myocardial infarction or stroke) in the diabetic compared to the non-diabetic subpopulation [40]. Similarly, the ARB telmisartan was non-inferior compared to ramipril with regard to the reduction of the composite of cardiovascular death, myocardial infarction and stroke with/without hospitalization (primary and secondary efficacy outcomes) in the subgroup of diabetic patients in the ONTARGET trial [44]. Moreover ACE inhibitors and ARBs were not only shown to reduce cardiovascular events in diabetics, but also to reduce the new onset of diabetes [40, 41, 43, 45, 46]. In addition, there are several smaller trials conducted specifically in diabetic patients that have demonstrated the efficacy of ACE inhibitors and ARBs on various surrogate end-points, most notably albuminuria. The benefit was seen in particular in patients with proteinuria [47–52].

Yet, despite these successful trials providing new options for cardio-protection, the high and increasing prevalence of metabolic disorders calls for further reduction of the cardiovascular risk. For example the RENAAAL study showed that even the appropriately treated diabetic patients were still at high cardiovascular and renal risk,
which could be predicted by the residual albuminuria after RAS blockade [53, 54].

One of the approaches to address this need was the development of ARBs with enhanced PPAR-γ activity [55]. Some data indicate that the activation of PPARs might contribute to the beneficial effects of certain ARBs, such as telmisartan and irbesartan or the losartan metabolite EXP3179 [56–60]. It was demonstrated, that chronic treatment with losartan [61] or with high-dose (160 mg/day) telmisartan [62] are able to activate PPAR-γ in circulating monocytes of patients with hypertension and metabolic syndrome, respectively. The activation of PPAR-γ, on one hand, exerts lipogenic effects, but on the other hand it stimulates adiponectin production along with its insulin-sensitizing effect [63]. A partial PPAR-γ agonism might play a positive role, especially in the context of AT1R blockade, which (via NF-κB inhibition) prevents PPAR-γ down-regulation [64]. However, antidiabetic actions were also observed under ARB treatment with low PPAR-γ activating potential such as valsartan in both preclinical [28] and clinical [43] settings. Thus, the extent of the contribution of PPAR-γ activating properties of the individual ARBs to their clinical antidiabetic outcomes has not been clearly defined [65]. The development of the previously reported metabolically targeted ARBs with PPAR-γ activity, such as K-868 or PF-03838135 did not advance to a clinical phase and no novel data have been reported for these agents [66]. Another putative approach to augment the cardio-protective actions of the ARBs is to complement the AT1R blockade with the activation of the “protective RAS”, i.e. by AT2R stimulation.

3.2 Angiotensin AT2 Receptor Agonists

While the current therapeutic strategies aim to prevent an undesired activation of the AT1R, stimulation of the AT2R might provide a mean to oppose many of the AT1R-mediated actions [26, 67, 68]. There is accumulating evidence for the cardio-protective action of the AT2R, which is based not only on indirect evidence, but also on the investigation of the effects of a direct AT2R stimulation. Treatment with the first non-peptide highly selective AT2R agonist, compound 21, prevented or reverted associated vascular remodeling in large and middle-sized arteries in either L-N²-Nitroarginine methyl ester (L-NAME) or spontaneously hypertensive rats (SHR) [69, 70]. Compound 21 also significantly reduced the ischemic area after middle cerebral artery occlusion in rats, along with antioxidant and anti-inflammatory effects (such as MCP-1 and TNF-α down-regulation) [71], and in rats with permanent coronary artery ligation it improved cardiac function and myocardial architecture early [72] and later after myocardial infarction [73]. Notably, the cardio-protective effects of AT2R stimulation were not associated with a reduction in blood pressure in these or other experiments when compound 21 was administered peripherally. Compound 21 is under physiological situation not able to cross the blood–brain barrier. However, when compound 21 was administered intracerebroventricularly it reduced blood pressure and exerted sympatholytic action (improved baroreflex sensitivity) in Wistar Kyoto rats and SHR. These effects were not affected by AT1R blockade, but were sensitive to NO-synthase blockade [74]. A similar sympatholytic action was observed after central AT2R stimulation in rats with ligation-induced heart failure [75].

The putative mechanisms behind the beneficial effects of AT2R stimulation include the activation of the NO/cyclic guanosine monophosphate (cGMP) pathway [76], down-regulation and inhibition of mitogen-activated protein kinases (MAPKs) by protein phosphatases [77, 78], or direct disruption of AT1R function by AT1R–AT2R heterodimerization [79]. With regard to cardio-metabolic disease, the anti-inflammatory effects of AT2R stimulation appear to be the most relevant. These include the inhibition of NF-κB activity as a result of 11,12-epoxeyicosatetraenoic acid epoxidation [80], augmented IL-10 production and T-cell differentiation to the Treg phenotype [81]. Indeed, the stimulation of the AT2R dose-dependently attenuated TLR-4 lipopolysaccharide (LPS)-induced TNF-α and IL-6 production but it increased IL-10 production via sustained selective extracellular-signal-regulated kinase 1/2 (ERK1/2) phosphorylation [82]. Similar anti-inflammatory effects were observed in human mononuclear cells [83] or in high-fat diet-induced vascular inflammation [84].

Concerning AT1R–AT2R interaction, it has to be noted that it might not only take place on the cell membrane by heterodimerization, as previously reported [79], but it might be more related to a negative cytoplasmatic cross-talk [85]. Moreover, the angiotensin receptor function might be modulated by receptor-associated proteins such as AT1 receptor-associated protein (ATRAP), AT1 receptor associated protein 1 (ARAP1) for the AT1R and AT2 receptor interacting protein (ATIP) or AT2 receptor binding protein of 50 kDa for the AT2R (the topic is discussed extensively elsewhere [86]).

There are several experimental data confirming the beneficial effects of AT2R stimulation in vivo and in animal models of metabolic disorders. In type 2 diabetic KKAY mice, compound 21 improved insulin sensitivity, increased adiponectin and reduced TNF-α levels, while protecting the pancreatic β-cells. These effects resulted in reduced body weight and fat mass within two weeks of treatment. Interestingly, the beneficial effects of AT2R activation were blocked by PPAR-γ inhibition [87]. In high-fructose/high-fat fed rats, compound 21 improved insulin sensitivity and glucose tolerance comparably to the ARB, losartan.
Moreover, compound 21 lowered triacylglyceride levels as well, an effect not seen by losartan treatment [88]. Very similar results were obtained in high-fat diet mice. In this model, compound 21 improved insulin sensitivity, reduced TNF-α, increased adiponectin and IL-10 levels, and reduced serum triacylglyceride levels. Again, the effects of AT2R stimulation were broader compared to the effects of the ARB (valsartan in this study), which improved glucose tolerance only. Notably, the effects of both compound 21 and valsartan seemed to be mediated via the AT2R as they were not observed in AT2R-KO mice [89]. These results are complemented by the in vitro data from 3T3-L1 adipocytes. In this cell line, compound 21 reduced TNF-α-induced IL-6 and MCP-1 expression, yet without activating PPAR-γ and without inducing adipocyte differentiation [90]. Therefore, it remains controversial, whether PPAR-γ activation is involved in the signaling cascade of the AT2R, at least in the cardio-metabolic area. The AT2R is not only abundantly expressed in pancreatic β-cell of adult rats, but its stimulation significantly improved insulin synthesis and secretion [91]. Moreover, compound 21 up-regulated superoxide dismutase expression, reduced oxidative load and caspase-3 expression and consequently prevented cell death of pancreatic β-cell in streptozotocin-induced diabetic rats [92].

Several further data indicate that the attenuation of inflammation and improvement of the metabolic profile by AT2R stimulation translates into nephroprotective effects. Such neproprotective effects have previously been reported in hypertensive models such as 2-kidney-1-clip renovascular hypertension [93] or in stroke-prone SHR [94]. The results on the protection against kidney damage observed in diabetic animals are in line with these findings in hypertensive models. In streptozotocin-induced diabetic rats, compound 21 normalized TNF-α and IL-6 levels and increased NO and cGMP with consequent attenuation of urinary albumin to creatinine ratio, yet without affecting blood pressure [95]. Similar protection against diabetic nephropathy was recently reported, in type 1 diabetic mice, in which compound 21 attenuated cystatin C levels, albuminuria, mesangial expansion, and glomerulosclerosis [96]. Therefore, it seems that compound 21 prevents albuminuria via normalization of the NO/cGMP pathway but mainly via reduction of renal inflammatory infiltration and subsequently the prevention structural alterations of the glomerular filter.

Finally, AT2R stimulation exerted anti-inflammatory and nephroprotective effects also in obese Zucker rats. In these rats, the peptide AT2R agonist CGP-42112A reduced systemic inflammation and oxidative load [97], and compound 21 reduced TNF-α expression, renal macrophage infiltration, fibrosis and albuminuria [98]. Although the effects in Zucker rats were not associated with blood pressure-lowering effect by AT2R stimulation, compound 21 prevented salt-sensitive hypertension in these rats. This hemodynamic effect, not generally observed in other animal models, might be related to reduced renal Ang II and AT1R and enhanced ACE2 and Ang (1–7) levels and AT2R expression [99] or to the natriuretic effect by compound 21, which might be unmasked under certain conditions [100–102].

It has to be noted, that the AT2R pathway might be stimulated by the Ang (1–7) produced by ACE2 as well. Congruently, ACE2 overexpression improved fasting glucose in diabetic mice [103] or vice-versa, the loss of ACE2 exaggerated high-calorie diet-induced insulin resistance [104]. However, due to receptor hetero-dimerization, the blockade of either AT2R or Mas receptor seems to block the effects of the other receptor [105]. Thus, we need to be cautious when attributing the effects of ACE2/Ang (1–7) stimulation to the activation of a particular receptor (AT2R or the Mas).

4 Combined Angiotensin Receptor Modulation

As described above, the RAS blockade currently represents the gold standard in cardiovascular therapy, including diabetic nephropathy. The mechanisms involved include direct blockade of the deleterious effects of Ang II but also indirect immune-modulatory effects. Similar mechanisms are involved in the beneficial (e.g. anti-inflammatory, insulin sensitizing, nephroprotective) effects of the stimulation of the “protective RAS” in various animal models of diabetes or obesity. Yet, because the mechanisms of AT2R stimulation and AT1R blockade are only partly overlapping as described above and display a certain complementarity, there might be a potential for the combination of the AT1R blockade and AT2R stimulation (Fig. 1).

The idea of dual hit in the RAS is not novel. Some early trials with surrogate end-points have investigated the potential benefit of dual RAS blockade with variable outcomes. In the CALM study in diabetic patients with microalbuminuria, the ACE inhibitor + ARB combination led to more pronounced reduction of microalbuminuria compared to either monotherapy [107], while no additive effect on albuminuria was observed in high-risk patients in the IMPROVE trial [108]. The combination of renin inhibition and losartan significantly reduced proteinuria in the AVOID study in diabetic patients with nephropathy [109, 110]. However, the results of the later studies with hard end-points: ONTARGET [44, 111] and ALTITUDE [112] advise against the use of dual RAS blockade. The ONTARGET trial in high-risk patients displayed more adverse events (such as hypotension, syncope, kidney dysfunction, hyperkalemia) in the combined arm (the ACE
inhibitor ramipril + the ARB telmisartan). The ALTITUDE trial, which tested the direct renin inhibitor, aliskiren, in diabetic patients with renal disease needed to be halted prematurely due to increased incidence of adverse events (slight numeric increase in stroke rates and significant increase in hyperkalemia and hypotension) in the aliskiren arm (on the background of ACE inhibition or ARB treatment). As such, the concept of dual RAS blockade failed primarily due to safety concerns. A recent meta-analysis demonstrated that dual therapy was associated with 66 % higher risk of hypotension [113]. It was hypothesized that lower blood pressure in the combination arm might have contributed to the increased incidence of renal end-points in the combination arm of the ONTARGET trial [114] and that the low blood pressure at baseline might be responsible for the renal dysfunction observed in the aliskiren arm of the ALTITUDE trial [115]. These considerations suggest that the second hit in the RAS should not “knock-out” the RAS completely in order to minimize the potential for undesired hypotension along with other unwarranted effects. With this regard, the activation of the AT2R represents a putatively better suited candidate for an add-on to the AT1R blocking strategies. Yet, because these considerations represent a translational approach with a very specific aim, only few experimental studies have investigated the effects of the combination of AT1R blockade with AT2R stimulation. Experiments in two animal models of hypertension (L-NAME and SHR) indicate that there is no significant additive blood pressure effect by AT2R stimulation when added to the ARB (olmesartan or losartan, respectively) [69, 70]. Nevertheless, a superior effect by the combination treatment on some aspects of vascular remodeling (most notably on hydroxyprolin/collagen content and arterial stiffness) over monotherapy was observed [69, 70]. Therefore a clinical rationale for combined angiotensin

![Diagram](image-url)
Combined angiotensin receptor modulation includes the AT1R blockade aimed at achieving target blood pressure values and the AT2R stimulation aimed to reduce arterial stiffness in the long term. Arterial stiffness is an independent predictor of cardiovascular events and all-cause mortality [116]. The reduction of arterial stiffness prevents the increase in the systolic blood pressure without compromising diastolic blood pressure values. Such a combined effect might be of particular significance in the elderly, in patients with isolated systolic hypertension or in end-stage renal patients.

At present, there is only one study which has investigated the effects of combined AT2R stimulation + AT1R blockade specifically in the setting of a metabolic disorder. In this study, compound 21 was tested in comparison and in combination with losartan in Zucker diabetic fatty rats. Add-on of compound 21 extended the reduction of albuminuria from 15 weeks of age (in the losartan group) to 20 weeks of age (the end of the experimental protocol). Moreover, while losartan reduced renal macrophage infiltration, TNF-α expression and glomerular and perivascular fibrosis, compound 21 reduced tubulointerstitial fibrosis (the best correlate for renal disease progression) as well. In the combination arm, there was also a slight numeric tendency for larger effect on glomerular and perivascular fibrosis compared to losartan alone. Consistent with previous studies, reduced triacylglyceride levels were observed only in groups treated with compound 21. Finally, compound 21 neither alone, nor in combination with losartan altered blood pressure, confirming that its beneficial effects are largely blood pressure-independent [98]. Due to these additional beneficial effects

![Combined Angiotensin Receptor Modulation](image)

**Fig. 2** Combined angiotensin receptor modulation. Scheme showing the rationale for combining the stimulation of the AT2 receptor (AT2R) with the blockade of the angiotensin AT1 receptor AT1R by the AT1R blockers (ARBs). The employment of the AT1R blockade is aimed at achieving target blood pressure values and the AT2R stimulation is aimed to reduce arterial stiffness in the long term. The reduction of arterial stiffness prevents the increase in the systolic blood pressure without compromising diastolic blood pressure values. Such a combined effect might be of particular significance in the elderly, in patients with isolated systolic hypertension or in end-stage renal patients.
of the add-on AT2R stimulation to AT1R blockade, such combination represents an interesting perspective for future clinical investigation.

5 Conclusion

The combined modulation of angiotensin receptors by AT1R blockade and simultaneous AT2R stimulation provides an intriguing novel therapeutic concept. This approach might be suitable in particular for patient populations with well-controlled blood pressure or where further blood pressure reduction is not desired. In addition, patients with chronic low-grade inflammation and/or isolated systolic hypertension might benefit from the anti-inflammatory and de-stiffening effects of the AT2R stimulation additive to the AT1R blockade. Yet, there are no clinical and only sparse pre-clinical in vivo data available for this approach. Thus, future studies on the combined angiotensin receptor modulation in the field of cardio-metabolic diseases represent an attractive and highly sought endeavor.

Compliance with Ethical Standards

Funding The work was supported by the Grants of the Scientific Grant Agency VEGA 1-0380-14 and Agency for Science and Research Support APVV 0205-11.

Conflicts of interest Ludovit Paulis, Sebastien Fouquier, Pawel Namsolleck, Chaiera Ricarti and Thomas Unger have no potential conflicts of interest that might be relevant to the contents of this review. Ulrike Steckelings has received short term student fellowship and free drug supply of compound 21 (for research work) from Vicore Pharma.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Combined Angiotensin Receptor Modulation


Δ Adis


